艾地苯醌对帕金森病认知障碍患者的疗效

doi:10.6040/j.issn.1671-7554.0.2024.0647

摘要/Abstract

摘要： 目的观察艾地苯醌对帕金森病认知障碍患者的治疗效果,并探讨其作用机制。方法纳入2017年1月至2024年1月在神经内科住院治疗的帕金森病认知障碍患者216例,随机分为常规治疗组(n=82)和艾地苯醌治疗组(n=134),分别监测两组在药物治疗前及连续药物治疗12个月后的蒙特利尔认知评估量表(Montreal Cognitive Assessment, MoCA)及其单领域认知评分,简易精神状态检查量表(Mini-Mental State Examination, MMSE)评分、统一帕金森评分量表Ⅲ(Unified Parkinsons Disease Rating Scale Ⅲ, UPDRS-Ⅲ)评分、胆碱能通路高信号量表(Cholinergic Pathways Hyperintensities Score, CHIPS)评分,白介素-6(interleukin-6, IL-6)、外周血超氧化物歧化酶(superoxide dismutase, SOD)、肝功能和肾功能指标变化情况。结果治疗前两组患者一般资料及Hoehn-Yahr(H-Y)分期差异无统计学意义(P>0.05),各项量表评分、血液学指标差异无统计学意义(P>0.05)。经过12个月药物治疗后,艾地苯醌治疗组MoCA评分及其单领域视空间执行能力、语言的评分增幅高于常规治疗组(P<0.05),UPDRS-Ⅲ评分下降幅度更加明显(P<0.05);艾地苯醌治疗组IL-6水平降低,常规治疗组IL-6水平升高,两组差异有统计学意义(P<0.05);艾地苯醌治疗组SOD水平增高,常规治疗组SOD水平降低,两组差异有统计学意义(P<0.05);两组肝功能、肾功能相关指标差异无统计学意义(P>0.05);调整了治疗前CHIPS评分、病程、年龄协变量后,治疗后艾地苯醌治疗组的CHIPS评分比常规治疗组低2.19分(F=229.16, P<0.01,R2=0.91,调整后R2=0.90)。结论艾地苯醌能够明显减轻帕金森病患者的认知障碍,改善运动症状,延缓白质高信号对胆碱能通路的损害,增加外周血SOD水平及降低IL-6水平。

关键词: 帕金森病, 认知障碍, 艾地苯醌, 运动症状, 胆碱能通路高信号量表

Abstract: Objective To investigate the therapeutic effects of idebenone in patients with Parkinsons disease-related cognitive impairment and to explore its mechanisms of action. Methods A total of 216 patients with Parkinsons disease-related cognitive impairment who were hospitalized in the The First Affiliated Hospital of Shandong First Medical University from January 2017 to January 2024 were included. The patients were randomly divided into the conventional treatment group(n=82)and the idebenone treatment group(n=134). The changes of the Montreal Cognitive Assessment(MoCA)and its subdomain cognitive scores, the Mini-Mental State Examination(MMSE), the Unified Parkinsons Disease Rating Scale Ⅲ(UPDRS-Ⅲ), the Cholinergic Pathways Hyperintensities Score(CHIPS), interleukin-6(IL-6), peripheral blood superoxide dismutase(SOD), liver function, and kidney function were monitored for both groups before drug treatment and after 12 months of continuous drug treatment. Results There were no statistically significant differences in general data, Hoehn-Yahr(H-Y)staging, various scale scores and hematological indicators before treatment(P>0.05). After 12 months of drug treatment, the increase in MoCA scores and their single-domain visuospatial executive ability and language was higher in the idebenone treatment group than in the conventional treatment group(P<0.05), and the decrease in UPDRS-Ⅲ scores was even more pronounced(P<0.05). The IL-6 levels in the idebenone treatment group decreased, while those in the conventional treatment group increased, with a statistically significant difference between the two groups(P<0.05). The SOD levels in the idebenone treatment group increased, while those in the conventional treatment group decreased, with a statistically significant difference between the two groups(P<0.05). There were no statistically significant differences in liver and kidney function-related indicators between the two groups(P>0.05). After adjusting for pre-treatment CHIPS scores, disease duration, and age covariates, the CHIPS score in the idebenone treatment group was 2.19 points lower than that in the conventional treatment group(F=229.16, P<0.01, R2=0.91, adjusted R2=0.90). Conclusion Idebenone can significantly alleviate cognitive impairment, improve motor symptoms, delay the damage of white matter hyperintensities to the cholinergic pathways, increase peripheral blood SOD levels, and reduce IL-6 levels in patients with Parkinsons disease.

Key words: Parkinsons disease, Cognitive impairment, Idebenone, Motor symptoms, Cholinergic Pathways Hyperintensities Score

中图分类号:

R741

任延红,李秀华,朱晓冉,方雨晴,赵张宁,毛飞,王雅琳,张艳青,刘天淏,徐新荣. 艾地苯醌对帕金森病认知障碍患者的疗效[J]. 山东大学学报 (医学版), 2024, 62(10): 106-114.

REN Yanhong, LI Xiuhua, ZHU Xiaoran, FANG Yuqing, ZHAO Zhangning, MAO Fei, WANG Yalin, ZHANG Yanqing, LIU Tianhao, XU Xinrong. Therapeutic efficacy of idebenone on cognitive impairment in patients with Parkinsons disease[J]. Journal of Shandong University (Health Sciences), 2024, 62(10): 106-114.

参考文献

[1] Aarsland D, Batzu L, Halliday GM, et al. Parkinson disease-associated cognitive impairment[J]. Nat Rev Dis Primers, 2021, 7(1): 47.
[2] Bäckström D, Granåsen G, Domellöf ME, et al. Early predictors of mortality in Parkinsonism and Parkinson disease: a population-based study[J]. Neurology, 2018, 91(22): e2045-e2056.
[3] Han JJ, Fan YH, Wu PP, et al. Parkinsons disease dementia: synergistic effects of alpha-synuclein, tau, beta-amyloid, and iron[J]. Front Aging Neurosci, 2021, 13: 743754. doi:10.3389/fnagi.2021.743754.
[4] Degirmenci Y, Angelopoulou E, Georgakopoulou VE, et al. Cognitive impairment in Parkinsons disease: an updated overview focusing on emerging pharmaceutical treatment approaches[J]. Medicina, 2023, 59(10): 1756.
[5] Gueven N, Ravishankar P, Eri R, et al. Idebenone: when an antioxidant is not an antioxidant[J]. Redox Biol, 2021, 38: 101812. doi:10.1016/j.redox.2020.101812.
[6] Jaber S, Polster BM. Idebenone and neuroprotection: antioxidant, pro-oxidant, or electron carrier?[J]. J Bioenerg Biomembr, 2015, 47(1/2): 111-118.
[7] Yan JQ, Sun WJ, Shen MM, et al. Idebenone improves motor dysfunction, learning and memory by regulating mitophagy in MPTP-treated mice[J]. Cell Death Discov, 2022, 8(1): 28.
[8] He PK, Gao YY, Lyu FJ, et al. Idebenone-activating autophagic degradation of α-synuclein via inhibition of AKT-mTOR pathway in a SH-SY5Y-A53T model of Parkinsons disease: a network pharmacological approach[J]. Evid Based Complement Alternat Med, 2021, 2021: 8548380. doi:10.1155/2021/8548380.
[9] Bocti C, Swartz RH, Gao FQ, et al. A new visual rating scale to assess strategic white matter hyperintensities within cholinergic pathways in dementia[J]. Stroke, 2005, 36(10): 2126-2131.
[10] Garcia-Ptacek S, Kramberger MG. Parkinson disease and dementia[J]. J Geriatr Psychiatry Neurol, 2016, 29(5): 261-270.
[11] Smith C, Malek N, Grosset K, et al. Neuropathology of dementia in patients with Parkinsons disease: a systematic review of autopsy studies[J]. J Neurol Neurosurg Psychiatry, 2019, 90(11): 1234-1243.
[12] Aarsland D, Creese B, Politis M, et al. Cognitive decline in Parkinson disease[J]. Nat Rev Neurol, 2017, 13(4): 217-231.
[13] Giorgio V, Petronilli V, Ghelli A, et al. The effects of idebenone on mitochondrial bioenergetics[J]. Biochim Biophys Acta, 2012, 1817(2): 363-369.
[14] Rauchová H. Coenzyme Q10 effects in neurological diseases[J]. Physiol Res, 2021, 70(l4): S683-S714.
[15] Cardoso SM, Pereira C, Oliveira CR. The protective effect of vitamin E, idebenone and reduced glutathione on free radical mediated injury in rat brain synaptosomes[J]. Biochem Biophys Res Commun, 1998, 246(3): 703-710.
[16] Lee HJ, Park JH, Hoe HS. Idebenone regulates aβ and LPS-induced neurogliosis and cognitive function through inhibition of NLRP3 inflammasome/IL-1β axis activation[J]. Front Immunol, 2022, 13: 749336. doi:10.3389/fimmu.2022.749336.
[17] 黄骥, 阳军, 欧阳娟, 等. 艾地苯醌联合多巴丝肼治疗帕金森病的临床研究[J]. 药物评价研究, 2020, 43(12): 2501-2504. HUANG Ji, YANG Jun, OUYANG Juan, et al. Clinical study on idebenone combined levodopa and benserazide hydrochloride in treatment of Parkinsons disease[J]. Drug Evaluation Research, 2020, 43(12): 2501-2504.
[18] 夏秋怡, 徐茂青, 霍青.艾地苯醌结合美多芭对帕金森患者的疗效、步态及精神状态的影响[J]. 卒中与神经疾病, 2020, 27(5): 627-630. XIA Qiuyi, XU Maoqing, HUO Qing, et al. The effects of idebenone combined with madopar on the efficacy, gait, and mental state of patients with parkinsons disease[J]. Stroke and Nervous Diseases, 2020, 27(5): 627-630.
[19] 赵海龙, 王皓, 方雨晴, 等. 增服艾地苯醌对34例帕金森病抑郁患者的疗效观察[J]. 山东大学学报(医学版), 2022, 60(4): 38-44. ZHAO Hailong, WANG Hao, FANG Yuqing, et al. Efficacy of additional idebenone in the treatment of 34 patients with Parkinsons disease with depression[J]. Journal of Shandong University(Health Sciences), 2022, 60(4): 38-44.
[20] 马秀娟, 朱宁, 朱洪山, 等. 艾地苯醌治疗帕金森病轻度认知障碍的临床疗效观察[J]. 世界最新医学信息文摘(连续型电子期刊), 2020, 20(16): 138-139, 141. MA Xiujuan, ZHU Ning, ZHU Hongshan, et al. Clinical effect of idebenone on mild cognitive impairment of Parkinsons disease[J]. World Latest Medicine Information(Continuous Electronic Journal), 2020, 20(16): 138-139, 141.
[21] Carbon M, Ma YL, Barnes A, et al. Caudate nucleus: influence of dopaminergic input on sequence learning and brain activation in Parkinsonism[J]. Neuroimage, 2004, 21(4): 1497-1507.
[22] Gatt AP, Duncan OF, Attems J, et al. Dementia in Parkinsons disease is associated with enhanced mitochondrial complex I deficiency[J]. Mov Disord, 2016, 31(3): 352-359.
[23] Lizama BN, Chu CT. Neuronal autophagy and mitophagy in Parkinsons disease[J]. Mol Aspects Med, 2021, 82: 100972. doi:10.1016/j.mam.2021.100972.
[24] 闫俊强, 刘安然, 黄家瑞, 等. 艾地苯醌对帕金森病模型小鼠行为学及脑组织线粒体自噬水平的影响[J]. 中华行为医学与脑科学杂志, 2021, 30(1): 15-21. YAN Junqiang, LIU Anran, HUANG Jiarui, et al. Effects of idebenone on behavior and mitochondrial autophagy of brain tissue in Parkinson disease model mice[J]. Chinese Journal of Behavioral Medicine and Brain Science, 2021, 30(1): 15-21.
[25] Liu H, Deng B, Xie F, et al. The influence of white matter hyperintensity on cognitive impairment in Parkinsons disease[J]. Ann Clin Transl Neurol, 2021, 8(9): 1917-1934.
[26] Shin J, Choi S, Lee JE, et al. Subcortical white matter hyperintensities within the cholinergic pathways of Parkinsons disease patients according to cognitive status[J]. J Neurol Neurosurg Psychiatry, 2012, 83(3): 315-321.
[27] Qi XM, Tang HD, Luo Q, et al. White matter hyperintensities predict cognitive decline: a community-based study[J]. Can J Neurol Sci, 2019, 46(4): 383-388.
[28] 张晓韬, 何天齐, 朱梅佳, 等.艾地苯醌联合治疗帕金森病疗效的临床观察[J].山东大学学报(医学版), 2019, 57(4): 34-41. ZHANG Xiaotao, HE Tianqi, ZHU Meijia, et al. Clinical observation of the effects of idebenone on Parkinsons disease[J]. Journal of Shandong University(Health Sciences), 2019, 57(4): 34-41.
[29] Dionísio PA, Amaral JD, Rodrigues CMP. Oxidative stress and regulated cell death in Parkinsons disease[J]. Ageing Res Rev, 2021, 67: 101263. doi:10.1016/j.arr.2021.101263.
[30] Pajares M, I Rojo A, Manda G, et al. Inflammation in Parkinsons disease: mechanisms and therapeutic implications[J]. Cells, 2020, 9(7): 1687.
[31] 刘震宇, 姚淑芳. 艾地苯醌联合多巴丝肼对帕金森患者血清SOD、MDA、8-OHdG水平的影响[J]. 现代诊断与治疗, 2021, 32(9): 1375-1377. LIU Zhenyu, YAO Shufang. Effects of idebenone combined with dobutamine on serum SOD, MDA and 8-OHdG levels in patients with Parkinsons disease[J]. Modern Diagnosis and Treatment, 2021, 32(9): 1375-1377.
[32] Avcı B, Günaydın C, Güvenç T, et al. Idebenone ameliorates rotenone-induced Parkinsons disease in rats through decreasing lipid peroxidation[J]. Neurochem Res, 2021, 46(3): 513-522.
[33] Tansey MG, Romero-Ramos M. Immune system responses in Parkinsons disease: early and dynamic[J]. Eur J Neurosci, 2019, 49(3): 364-383.
[34] Yan AJ, Liu ZH, Song L, et al. Idebenone alleviates neuroinflammation and modulates microglial polarization in LPS-stimulated BV2 cells and MPTP-induced Parkinsons disease mice[J]. Front Cell Neurosci, 2018, 12: 529. doi:10.3389/fncel.2018.00529.
[35] Fakhoury M. Microglia and astrocytes in Alzheimers disease: implications for therapy[J]. Curr Neuropharmacol, 2018, 16(5): 508-518.
[36] Li DM, Zhang G, Wang ZY, et al. Idebenone attenuates ferroptosis by inhibiting excessive autophagy via the ROS-AMPK-mTOR pathway to preserve cardiac function after myocardial infarction[J]. Eur J Pharmacol, 2023, 943: 175569. doi:10.1016/j.ejphar.2023.175569.

多维度评价

Viewed

Full text

Abstract

Cited

Shared

Discussed